American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Abdel-Wahab
    Abdel-Wahab
  10. Kernan
    Kernan

Groups

  1. Department of Medicine (3950)
  2. Hematologic Malignancies, Division of (3750)
  3. Center for Hematologic Malignancies (3637)
  4. GSK Faculty (1584)
  5. Adult Leukemia (1328)
  6. Sloan Kettering Institute Faculty (1071)
  7. Bone Marrow Transplant (967)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (952)
  9. Lymphoma (928)
  10. Tow Center for Developmental Oncology (TCDO) (878)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1242)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3950)
  2. Hematologic Malignancies, Division of (3750)
  3. Center for Hematologic Malignancies (3637)
  4. GSK Faculty (1584)
  5. Adult Leukemia (1328)
  6. Sloan Kettering Institute Faculty (1071)

More Groups

People
  1. Sergio Giralt (346)
  2. Andrew Zelenetz (340)
  3. Ross Levine (315)
  4. Miguel-Angel Perales (303)
  5. Martin Tallman (300)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (46)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5165)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5537)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cytogenetics in hairy cell leukemia at diagnosis and relapse: The rate of therapy-related myeloid malignancies is low
    Meeting Abstract

    Getta, B.; Abdel-Wahab, O.; Park, J. H.; Tallman, M. S.
    Blood (2015)

    Fulltext@MSK | Save
  • Targeted sequencing reveals a relationship between mutational burden and clinical phenotype in MPNs
    Meeting Abstract

    Getta, B.; Rapaport, F.; Devlin, S.; Zhao, C.; Knapp, K. M.; Patel, M.; Mohanty, A.; Van den Brink, M.; Levine, R. L.; Arcila, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Herpes zoster is more frequent in patients receiving higher cumulative doses of arsenic trioxide and is mitigated by prophylactic acyclovir
    Meeting Abstract

    Glass, J. L.; Kishtagari, A.; Douer, D.; Tallman, M. S.
    Blood (2015)

    Fulltext@MSK | Save
  • An HSP90 inhibitor, PU-H71, antagonizes stroma-induced pro-survival effects in CLL through its inhibition of multi-component B-cell receptor signaling pathway
    Meeting Abstract

    Guo, A. L.; Lu, P.; Zhen, C.; Chiosis, G.; Wang, Y. L.
    Blood (2015)

    Fulltext@MSK | Save
  • Phase 1/1b study of the novel immunotoxin MT-3724 in relapsed/refractory non-Hodgkin's B-cell lymphoma (NHL)
    Meeting Abstract

    Hamlin, P. A.; Diefenbach, C. S.; Valacer, D. J.; Higgins, J.; Fanale, M. A.
    Blood (2015)

    Fulltext@MSK | Save
  • Clinical and correlative results of a phase 1 study of cerdulatinib (PRT062070) a dual SYK/JAK inhibitor in patients with relapsed/refractory B cell malignancies
    Meeting Abstract

    Hamlin, P. A.; Flinn, I.; Wagner-Johnston, N.; Burger, J. A.; Michelson, G.; Pandey, A.; Birrell, M.; Coffey, G. P.; Leeds, J. M.; Curnutte, J. T.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Adoptively transferred CMV-specific T-cells responsive to immunodominant CMVpp65 epitopes extend durable in-vivo suppression of clonogenic CMVpp65 [+] human colon carcinoma cells in comparison to T-cells responsive to subdominant epitopes
    Meeting Abstract

    Hasan, A. N.; Selvakumar, A.; Kuo, T. Y.; O'Reilly, R. J.
    Blood (2015)

    Fulltext@MSK | Save
  • The RIG-I agonist 3pRNA synergizes with checkpoint blockade in cancer immunotherapy
    Meeting Abstract

    Heidegger, S.; Kreppel, D.; Bscheider, M.; Wintges, A.; Bek, S.; Schmickl, M.; Ruland, J.; Peschel, C.; van den Brink, M.; Haas, T.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
    Meeting Abstract

    Chen, R.; Gopal, A. K.; Smith, S. E.; Ansell, S.; Rosenblatt, J. D.; Savage, K. J.; Connors, J. M.; Engert, A.; Larsen, E. K.; Huebner, D.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Phase I multicenter trial of brentuximab vedotin for steroid refractory acute graft-vs-host disease (GVHD)
    Meeting Abstract

    Chen, Y. B.; Li, S.; Konkel, S.; Loiselle, C.; Efebera, Y. A.; Devine, S. M.; El-Jawahri, A.; McAfee, S. L.; Soiffer, R. J.; Ritz, J.; more...
    Blood (2015)

    Fulltext@MSK | Save